ArriVent BioPharma, Inc. (AVBP) Institutional Ownership

Ownership Summary

ArriVent BioPharma, Inc. (NASDAQ:AVBP) showed up in the 13F filings of 119 institutional investors as of December 2025.

• These investors held 94.3% of outstanding shares in December 2025, up from 92.1% in September 2025.
• They increased total shares held in ArriVent BioPharma by 8.21% from last quarter, and the number of investors in AVBP increased 46.91% annually.
• Of these 119 holders, 69 added to their stakes in ArriVent BioPharma, 36 trimmed positions, and 14 made no changes.
• Combined, these investors held 39.53Mn shares in AVBP for December 2025, up by 3.0Mn shares quarter on quarter, and up 10.82Mn shares year over year.
• As of December 31, 2025, the biggest holder of ArriVent BioPharma is SUVRETTA CAPITAL MANAGEMENT, LLC at 4.4Mn shares, representing 10.5% of shares outstanding.
• Leading buyers of ArriVent BioPharma shares for the quarter ending December 2025 were VANGUARD CAPITAL MANAGEMENT LLC (1.53Mn), Vivo Capital, LLC (885.92K), Point72 Asset Management, L.P. (531.54K), Fund 1 Investments, LLC (499.99K), BALYASNY ASSET MANAGEMENT L.P. (383.25K).
• The largest sales of AVBP for the quarter ending December 2025 came from FMR LLC (687.44K), Goldman Sachs Group Inc (631.62K), CITADEL ADVISORS LLC (292.35K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (211.93K), Squarepoint Ops LLC (131.06K).
• Business Quant data shows the 10 biggest positions in ArriVent BioPharma as of December 2025 are held by SUVRETTA CAPITAL MANAGEMENT, LLC (4.4Mn), INFINITUM ASSET MANAGEMENT, LLC (4.15Mn), HHLR ADVISORS, LTD. (3.93Mn), ORBIMED ADVISORS LLC (3.03Mn), FMR LLC (3.02Mn), BlackRock, Inc. (2.53Mn), Octagon Capital Advisors LP (1.97Mn), Novo Holdings A/S (1.94Mn), Sofinnova Investments, Inc. (1.7Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.53Mn).